S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Provention Bio Stock Forecast, Price & News

-0.44 (-6.39%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
590,544 shs
Average Volume
1.41 million shs
Market Capitalization
$408.77 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio logo

About Provention Bio

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.


UBS Group Upgrades Provention Bio (NASDAQ:PRVB) to Outperform
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.12 per share


Net Income
$-98.58 million
Pretax Margin




Free Float
Market Cap
$408.77 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.41 out of 5 stars

Medical Sector

182nd out of 1,390 stocks

Pharmaceutical Preparations Industry

74th out of 668 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio
or view top-rated stocks.

How has Provention Bio's stock price been impacted by Coronavirus (COVID-19)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB stock has decreased by 28.4% and is now trading at $6.45.
View which stocks have been most impacted by COVID-19

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Provention Bio

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.08. The company earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. During the same quarter in the prior year, the company earned ($0.56) earnings per share.
View Provention Bio's earnings history

What price target have analysts set for PRVB?

8 analysts have issued 1-year price objectives for Provention Bio's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Provention Bio's share price to reach $17.75 in the next twelve months. This suggests a possible upside of 175.2% from the stock's current price.
View analysts' price targets for Provention Bio
or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:
  • Ashleigh W. Palmer, Chief Executive Officer & Director
  • Eleanor Leni Ramos, Chief Operating & Medical Officer
  • Andrew T. Drechsler, Chief Financial Officer
  • Francisco Leon, Chief Scientific Officer
  • Alex Rabiee, Vice President-Business Development

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Geode Capital Management LLC (1.64%), Millennium Management LLC (1.24%), Verition Fund Management LLC (1.13%), DG Capital Management LLC (0.86%) and Rice Hall James & Associates LLC (0.38%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends for Provention Bio

Which major investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Goldman Sachs Group Inc., 683 Capital Management LLC, BlackRock Inc., Jane Street Group LLC, New York State Common Retirement Fund, Wolverine Trading LLC, and California State Teachers Retirement System.
View insider buying and selling activity for Provention Bio
or view top insider-selling stocks.

Which major investors are buying Provention Bio stock?

PRVB stock was bought by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, DG Capital Management LLC, Millennium Management LLC, Geode Capital Management LLC, Barclays PLC, Two Sigma Investments LP, Morgan Stanley, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, and Jason Hoitt.
View insider buying and selling activity for Provention Bio
or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $6.45.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $408.77 million. The company earns $-98.58 million in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 59 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

Where are Provention Bio's headquarters?

Provention Bio is headquartered at P.O. BOX 666, OLDWICK NJ, 08858.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at (908) 428-9136 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.